|FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study|
C Tournigand, T André, E Achille, G Lledo, M Flesh, D Mery-Mignard, ...
Journal of Clinical Oncology 22 (2), 229-237, 2004
|Adjuvant trastuzumab in HER2-positive breast cancer|
D Slamon, W Eiermann, N Robert, T Pienkowski, M Martin, M Press, ...
New England Journal of Medicine 365 (14), 1273-1283, 2011
|Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis|
C Sotiriou, P Wirapati, S Loi, A Harris, S Fox, J Smeds, H Nordgren, ...
Journal of the National Cancer Institute 98 (4), 262-272, 2006
|Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer|
M Buyse, S Loi, L Van't Veer, G Viale, M Delorenzi, AM Glas, ...
Journal of the National Cancer Institute 98 (17), 1183-1192, 2006
|Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women …|
P McGale, C Taylor, C Correa, D Cutter, F Duane, M Ewertz, R Gray, ...
Lancet (London, England) 383 (9935), 2014
|Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.|
R Peto, C Davies, J Godwin, R Gray, HC Pan, M Clarke, D Cutter, S Darby, ...
Lancet (London, England) 379 (9814), 432-444, 2011
|Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases|
U Pastorino, M Buyse, G Friedel, RJ Ginsberg, P Girard, P Goldstraw, ...
The Journal of thoracic and cardiovascular surgery 113 (1), 37-49, 1997
|Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-> T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab …|
Breast Cancer Res Treat 94, S5, 2005
|Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series|
C Desmedt, F Piette, S Loi, Y Wang, F Lallemand, B Haibe-Kains, G Viale, ...
Clinical cancer research 13 (11), 3207-3214, 2007
|OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a GERCOR study|
C Tournigand, A Cervantes, A Figer, G Lledo, M Flesch, M Buyse, ...
Journal of clinical oncology 24 (3), 394-400, 2006
|Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen|
M Dowsett, J Cuzick, J Ingle, A Coates, J Forbes, J Bliss, M Buyse, ...
Journal of Clinical Oncology 28 (3), 509-518, 2010
|The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer|
MEL Van Der Burg, M Van Lent, M Buyse, A Kobierska, N Colombo, ...
New England Journal of Medicine 332 (10), 629-634, 1995
|Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade|
S Loi, B Haibe-Kains, C Desmedt, F Lallemand, AM Tutt, C Gillet, P Ellis, ...
Journal of clinical oncology 25 (10), 1239, 2007
|Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer|
Early Breast Cancer Trialists' Collaborative Group
New England journal of medicine 319 (26), 1681-1692, 1988
|Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes|
C Desmedt, B Haibe-Kains, P Wirapati, M Buyse, D Larsimont, ...
Clinical cancer research 14 (16), 5158-5165, 2008
|Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC).|
A Gerard, M Buyse, B Nordlinger, J Loygue, F Pène, P Kempf, JF Bosset, ...
Annals of surgery 208 (5), 606, 1988
|Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis.|
X Paoletti, K Oba, T Burzykowski, S Michiels, Y Ohashi, JP Pignon, ...
Jama 303 (17), 1729-1737, 2010
|Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials|
DJ Sargent, HS Wieand, DG Haller, R Gray, JK Benedetti, M Buyse, ...
Journal of Clinical Oncology 23 (34), 8664-8670, 2005
|The validation of surrogate endpoints in meta-analyses of randomized experiments|
M Buyse, G Molenberghs, T Burzykowski, D Renard, H Geys
Biostatistics 1 (1), 49-67, 2000
|Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials|
D Sargent, A Sobrero, A Grothey, MJ O'Connell, M Buyse, T Andre, ...
Journal of Clinical Oncology 27 (6), 872, 2009